This site uses cookies to provide you with a more responsive and personalised service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print page

    More

    Page   1/4   
  • 2014 Global health care sector outlook
    Read the press release to learn more.
  • 2014 Global health care sector outlook
    Report examines the current state of the global health care sector, provides a snapshot of activity in a number of geographic markets, and suggests considerations for stakeholders as they address funding, cost and other issues.
  • 2014 Global life sciences sector outlook
    Report outlines the top issues facing global life sciences stakeholders, provides a snapshot of activity in a number of geographic markets, and suggests considerations for companies as they seek to grow revenue and market share in 2014 and beyond.
  • Global life sciences sector positioned for success in 2014 despite macro pressures
    This report outlines the top issues facing global life sciences stakeholders, provides a snapshot of activity in a number of geographic markets, and suggests considerations for companies as they seek to grow revenue and market share in 2014 and beyond.
  • 2013 Financial Times Global Pharma/Biotech Conference
    Life sciences & health care collection spotlights Deloitte reports and involvement at Financial Times Global Pharmaceutical and Biotechnology Conference 2013.
  • Transformation beyond reform
    Explore key topics from the Financial Times U.S. Healthcare and Life Sciences Conference, held 6 June 2013.
  • Health care reform and life sciences: Threat, opportunity or both?
    Changing innovation processes and sales models crucial for companies to get ahead
  • Deloitte 2013 global life sciences outlook: Industry adopting new business model to address changing landscape, declining profit
    The DTTL report, 2013 global life sciences outlook: Optimism tempered by reality in a “new normal”, concludes that there are several drivers, such as patent expirations, regulatory scrutiny and shifts in innovations are prompting change in the industry.
  • Page   1/4   

 

Get connected
Share your comments

 

More on Deloitte
Learn about our site

 


Stay connected
  • Facebook RSS